GV.PA Genomic Vision EURONEXT €0.002 pre-market: heavy volume, watch upside
On 27 Jan 2026 pre-market we see GV.PA stock trading at €0.002 on EURONEXT after a strong intraday volume spike of 38.49M shares, about 2.71x its 50-day average. That surge makes Genomic Vision (GV.PA) one of the most active small-caps in the Healthcare sector this session and sets the stage for volatile price action as traders reassess liquidity, valuation and news flow.
Pre-market snapshot and what moved the tape
GV.PA stock opened pre-market at €0.002 with a day range between €0.002 and €0.002 and showed a one-session change near +5.88% versus the prior close. Volume of 38.49M versus an average of 14.22M pushed relative volume to 2.71, marking the stock as most active in early trade on EURONEXT.
Fundamentals at a glance: valuation and cash metrics
Genomic Vision (GV.PA) posts a market capitalization of roughly €0.69M with 385,105,984 shares outstanding and trailing EPS of -0.11, producing a negative PE. Price-to-sales is 0.47 and enterprise value to sales is 1.60, reflecting deep discounting relative to larger healthcare peers. The company reports cash per share near €0.006 and a current ratio of 0.91, indicating tight short-term liquidity versus sector averages.
Technical picture and liquidity indicators
The share price sits well below its 50-day average (€0.005) and 200-day average (€0.014), showing a long-term downtrend and weak technicals. Short-term traders should note the day low €0.002 and day high €0.002, while the heavy turnover raises execution risk for large block trades despite improved intraday liquidity.
Meyka AI grade and model forecast
Meyka AI rates GV.PA with a score out of 100: 58.64 | Grade: C+ | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals and is informational, not investment advice.
Meyka AI’s forecast model projects price paths
Meyka AI’s forecast model projects a 12-month base-case price of €0.0025, a conservative upside of +38.89% from the current €0.002, and a downside scenario to €0.0012 under continued cash stress. Forecasts are model-based projections and not guarantees.
Catalysts and risks for traders
Catalysts include product approvals, commercial rollouts of FiberVision systems, and partnership updates with Quest Diagnostics or research institutions. Key risks are continuing negative net income, low working capital, high enterprise value relative to market cap and thin absolute market capitalization, which can amplify volatility and bid-ask spreads on EURONEXT.
Final Thoughts
GV.PA stock is the session’s most active small-cap on EURONEXT on 27 Jan 2026, driven by a volume spike to 38.49M shares and a pre-market quote at €0.002. Fundamentals show negative earnings (EPS -0.11), a tiny market cap (€0.69M) and a current ratio below sector norms, all of which support Meyka AI’s cautious C+ HOLD grade. From a trading perspective the stock now offers high intraday liquidity but elevated execution and dilution risk. For investors considering GV.PA Genomic Vision SA stock, watch near-term news on commercial deals or clinical validation, and use strict position-sizing. Meyka AI’s forecast model projects a 12-month base-case €0.0025 (implied +38.89%) and a downside reference €0.0012 if cash metrics deteriorate. These figures are model-based projections and not guarantees; trade the volatility with clear stop levels and verify updates via company releases and official filings. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice.
FAQs
What is the current price and volume for GV.PA stock pre-market?
Pre-market on 27 Jan 2026 GV.PA stock trades near €0.002 with volume at 38.49M shares, about 2.71x its average, making it one of the most active names on EURONEXT.
What drivers should traders watch for GV.PA analysis?
Traders should watch partnership news, FiberVision commercial updates, clinical validation milestones and any financing announcements, as these materially affect GV.PA stock liquidity and short-term price moves.
How does Meyka AI rate GV.PA and what does the forecast show?
Meyka AI rates GV.PA with a score out of 100: 58.64 (C+) with suggestion HOLD. The model projects a 12-month base-case €0.0025, implying about +38.89%, with downside risks noted.
Is GV.PA a buy for long-term investors?
GV.PA Genomic Vision SA stock shows high risk: negative earnings, tight liquidity and a small market cap. Long-term investors should require clear commercial progress or financing before adding exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
